Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69


Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy.

De Velasco MA, Kura Y, Sakai K, Hatanaka Y, Davies BR, Campbell H, Klein S, Kim Y, MacLeod AR, Sugimoto K, Yoshikawa K, Nishio K, Uemura H.

JCI Insight. 2019 Sep 5;4(17). pii: 122688. doi: 10.1172/jci.insight.122688.


Smartwatch for the analysis of rest tremor in patients with Parkinson's disease.

López-Blanco R, Velasco MA, Méndez-Guerrero A, Romero JP, Del Castillo MD, Serrano JI, Rocon E, Benito-León J.

J Neurol Sci. 2019 Jun 15;401:37-42. doi: 10.1016/j.jns.2019.04.011. Epub 2019 Apr 9.


HOXA10 expression profiling in prostate cancer.

Hatanaka Y, de Velasco MA, Oki T, Shimizu N, Nozawa M, Yoshimura K, Yoshikawa K, Nishio K, Uemura H.

Prostate. 2019 Apr;79(5):554-563. doi: 10.1002/pros.23761. Epub 2019 Jan 6.


Generation of PTEN‑knockout (‑/‑) murine prostate cancer cells using the CRISPR/Cas9 system and comprehensive gene expression profiling.

Takao A, Yoshikawa K, Karnan S, Ota A, Uemura H, De Velasco MA, Kura Y, Suzuki S, Ueda R, Nishino T, Hosokawa Y.

Oncol Rep. 2018 Nov;40(5):2455-2466. doi: 10.3892/or.2018.6683. Epub 2018 Sep 5.


Interaction with touchscreen smartphones in patients with essential tremor and healthy individuals.

López-Blanco R, Benito-León J, Llamas-Velasco S, Del Castillo MD, Serrano JI, Rocon E, Romero JP, Velasco MA.

Neurologia. 2018 Aug 10. pii: S0213-4853(18)30178-6. doi: 10.1016/j.nrl.2018.05.005. [Epub ahead of print] English, Spanish.


Improvement of mouse controlling in Essential tremor by a tremor filter: A case report.

López-Blanco R, Méndez-Guerrero A, Velasco MA.

J Neurol Sci. 2018 Jul 15;390:87-88. doi: 10.1016/j.jns.2018.04.019. Epub 2018 Apr 12.


Essential tremor quantification based on the combined use of a smartphone and a smartwatch: The NetMD study.

López-Blanco R, Velasco MA, Méndez-Guerrero A, Romero JP, Del Castillo MD, Serrano JI, Benito-León J, Bermejo-Pareja F, Rocon E.

J Neurosci Methods. 2018 Jun 1;303:95-102. doi: 10.1016/j.jneumeth.2018.02.015. Epub 2018 Feb 23.


Prostate cancer immunotherapy: where are we and where are we going?

De Velasco MA, Uemura H.

Curr Opin Urol. 2018 Jan;28(1):15-24. doi: 10.1097/MOU.0000000000000462. Review.


SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide to modulate SCF- and or KIT-expressing cell functions.

Chen LL, Zhu J, Schumacher J, Wei C, Ramdas L, Prieto VG, Jimenez A, Velasco MA, Tripp SR, Andtbacka RHI, Gouw L, Rodgers GM, Zhang L, Chan BK, Cassidy PB, Benjamin RS, Leachman SA, Frazier ML.

PLoS One. 2017 Sep 7;12(9):e0184154. doi: 10.1371/journal.pone.0184154. eCollection 2017.


Evaluation of cervical posture improvement of children with cerebral palsy after physical therapy based on head movements and serious games.

Velasco MA, Raya R, Muzzioli L, Morelli D, Otero A, Iosa M, Cincotti F, Rocon E.

Biomed Eng Online. 2017 Aug 18;16(Suppl 1):74. doi: 10.1186/s12938-017-0364-5.


Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status.

Sakai K, Ukita M, Schmidt J, Wu L, De Velasco MA, Roter A, Jevons L, Nishio K, Mandai M.

Cancer Lett. 2017 Oct 1;405:22-28. doi: 10.1016/j.canlet.2017.07.013. Epub 2017 Jul 19.


Surgical treatment of acromioclavicular dislocation using the endobutton.

Teodoro RL, Nishimi AY, Pascarelli L, Bongiovanni RR, Velasco MAP, Dobashi ET.

Acta Ortop Bras. 2017 May-Jun;25(3):81-84. doi: 10.1590/1413-785220172503166657.


Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib.

Banno E, Togashi Y, de Velasco MA, Mizukami T, Nakamura Y, Terashima M, Sakai K, Fujita Y, Kamata K, Kitano M, Kudo M, Nishio K.

Int J Oncol. 2017 Jun;50(6):2049-2058. doi: 10.3892/ijo.2017.3961. Epub 2017 Apr 18.


Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.

Chiba M, Togashi Y, Bannno E, Kobayashi Y, Nakamura Y, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.

BMC Cancer. 2017 Apr 19;17(1):281. doi: 10.1186/s12885-017-3263-z. No abstract available.


MEK inhibitors against MET-amplified non-small cell lung cancer.

Chiba M, Togashi Y, Tomida S, Mizuuchi H, Nakamura Y, Banno E, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.

Int J Oncol. 2016 Dec;49(6):2236-2244. doi: 10.3892/ijo.2016.3736. Epub 2016 Oct 17.


FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.

Hibi M, Kaneda H, Tanizaki J, Sakai K, Togashi Y, Terashima M, De Velasco MA, Fujita Y, Banno E, Nakamura Y, Takeda M, Ito A, Mitsudomi T, Nakagawa K, Okamoto I, Nishio K.

Cancer Sci. 2016 Nov;107(11):1667-1676. doi: 10.1111/cas.13071.


Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.

Kaibori M, Sakai K, Ishizaki M, Matsushima H, De Velasco MA, Matsui K, Iida H, Kitade H, Kwon AH, Nagano H, Wada H, Haji S, Tsukamoto T, Kanazawa A, Takeda Y, Takemura S, Kubo S, Nishio K.

Oncotarget. 2016 Aug 2;7(31):49091-49098. doi: 10.18632/oncotarget.10077.


Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?

Banno E, Togashi Y, Nakamura Y, Chiba M, Kobayashi Y, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.

Cancer Sci. 2016 Aug;107(8):1134-40. doi: 10.1111/cas.12980. Epub 2016 Jul 14.


Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.

Nakamura Y, Togashi Y, Nakahara H, Tomida S, Banno E, Terashima M, Hayashi H, de Velasco MA, Sakai K, Fujita Y, Okegawa T, Nutahara K, Hamada S, Nishio K.

Mol Cancer Ther. 2016 Aug;15(8):1988-97. doi: 10.1158/1535-7163.MCT-15-0737. Epub 2016 May 20.


Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.

Mizukami T, Togashi Y, Naruki S, Banno E, Terashima M, de Velasco MA, Sakai K, Yoneshige A, Hayashi H, Fujita Y, Tomida S, Nakajima TE, Fujino T, Boku N, Ito A, Nakagawa K, Nishio K.

Mol Carcinog. 2017 Jan;56(1):106-117. doi: 10.1002/mc.22476. Epub 2016 Feb 24.


Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.

De Velasco MA, Kura Y, Yoshikawa K, Nishio K, Davies BR, Uemura H.

Oncotarget. 2016 Mar 29;7(13):15959-76. doi: 10.18632/oncotarget.7557.


Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.

Terashima M, Togashi Y, Sato K, Mizuuchi H, Sakai K, Suda K, Nakamura Y, Banno E, Hayashi H, De Velasco MA, Fujita Y, Tomida S, Mitsudomi T, Nishio K.

Clin Cancer Res. 2016 Jul 15;22(14):3663-71. doi: 10.1158/1078-0432.CCR-15-2093. Epub 2016 Jan 29.


Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomas.

Yoshioka Y, Togashi Y, Chikugo T, Kogita A, Taguri M, Terashima M, Mizukami T, Hayashi H, Sakai K, de Velasco MA, Tomida S, Fujita Y, Tokoro T, Ito A, Okuno K, Nishio K.

Cancer. 2015 Dec 15;121(24):4359-68. doi: 10.1002/cncr.29676. Epub 2015 Oct 21.


EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.

Mizukami T, Togashi Y, Sogabe S, Banno E, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Nakajima TE, Boku N, Nishio K.

Int J Oncol. 2015 Aug;47(2):499-505. doi: 10.3892/ijo.2015.3050. Epub 2015 Jun 16.


An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer.

Togashi Y, Mizuuchi H, Kobayashi Y, Hayashi H, Terashima M, Sakai K, Banno E, Mizukami T, Nakamura Y, de Velasco MA, Fujita Y, Tomida S, Mitsudomi T, Nishio K.

Ann Oncol. 2015 Aug;26(8):1800-1. doi: 10.1093/annonc/mdv240. Epub 2015 May 22. No abstract available.


Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.

Sakai K, Tsurutani J, Yamanaka T, Yoneshige A, Ito A, Togashi Y, De Velasco MA, Terashima M, Fujita Y, Tomida S, Tamura T, Nakagawa K, Nishio K.

PLoS One. 2015 May 8;10(5):e0121891. doi: 10.1371/journal.pone.0121891. eCollection 2015.


Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.

Yamamoto Y, De Velasco MA, Kura Y, Nozawa M, Hatanaka Y, Oki T, Ozeki T, Shimizu N, Minami T, Yoshimura K, Yoshikawa K, Nishio K, Uemura H.

J Transl Med. 2015 May 8;13:150. doi: 10.1186/s12967-015-0509-x.


Design, materials, and mechanobiology of biodegradable scaffolds for bone tissue engineering.

Velasco MA, Narváez-Tovar CA, Garzón-Alvarado DA.

Biomed Res Int. 2015;2015:729076. doi: 10.1155/2015/729076. Epub 2015 Mar 26. Review.


New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles.

Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco MA, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H.

Int Immunopharmacol. 2015 May;26(1):133-8. doi: 10.1016/j.intimp.2015.03.023. Epub 2015 Mar 27.


Conditional PTEN-deficient mice as a prostate cancer chemoprevention model.

Koike H, Nozawa M, De Velasco MA, Kura Y, Ando N, Fukushima E, Yamamoto Y, Hatanaka Y, Yoshikawa K, Nishio K, Uemura H.

Asian Pac J Cancer Prev. 2015;16(5):1827-31.


Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.

Togashi Y, Hayashi H, Okamoto K, Fumita S, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Nakagawa K, Nishio K.

Lung Cancer. 2015 Apr;88(1):16-23. doi: 10.1016/j.lungcan.2015.01.027. Epub 2015 Feb 7.


Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer.

Sakai K, Yoneshige A, Ito A, Ueda Y, Kondo S, Nobumasa H, Fujita Y, Togashi Y, Terashima M, De Velasco MA, Tomida S, Nishio K.

Springerplus. 2015 Jan 5;4:7. doi: 10.1186/2193-1801-4-7. eCollection 2015.


Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.

Kogita A, Togashi Y, Hayashi H, Banno E, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Takeyama Y, Okuno K, Nakagawa K, Nishio K.

Int J Oncol. 2015 Mar;46(3):1025-30. doi: 10.3892/ijo.2014.2797. Epub 2014 Dec 15.


Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer.

Togashi Y, Kogita A, Sakamoto H, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Kitano M, Okuno K, Kudo M, Nishio K.

Cancer Lett. 2015 Jan 28;356(2 Pt B):819-27. doi: 10.1016/j.canlet.2014.10.037. Epub 2014 Nov 4.


Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.

Togashi Y, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Nakagawa K, Nishio K.

J Thorac Oncol. 2015 Jan;10(1):93-101. doi: 10.1097/JTO.0000000000000353.


MEK inhibitor for gastric cancer with MEK1 gene mutations.

Sogabe S, Togashi Y, Kato H, Kogita A, Mizukami T, Sakamoto Y, Banno E, Terashima M, Hayashi H, de Velasco MA, Sakai K, Fujita Y, Tomida S, Yasuda T, Takeyama Y, Okuno K, Nishio K.

Mol Cancer Ther. 2014 Dec;13(12):3098-106. doi: 10.1158/1535-7163.MCT-14-0429. Epub 2014 Sep 24.


Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines.

Terashima M, Sakai K, Togashi Y, Hayashi H, De Velasco MA, Tsurutani J, Nishio K.

Springerplus. 2014 Aug 8;3:417. doi: 10.1186/2193-1801-3-417. eCollection 2014.


Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition.

Kogita A, Togashi Y, Hayashi H, Sogabe S, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Takeyama Y, Okuno K, Nakagawa K, Nishio K.

Int J Oncol. 2014 Oct;45(4):1430-6. doi: 10.3892/ijo.2014.2574. Epub 2014 Aug 1.


KIAA1199 interacts with glycogen phosphorylase kinase β-subunit (PHKB) to promote glycogen breakdown and cancer cell survival.

Terashima M, Fujita Y, Togashi Y, Sakai K, De Velasco MA, Tomida S, Nishio K.

Oncotarget. 2014 Aug 30;5(16):7040-50.


Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer.

De Velasco MA, Tanaka M, Yamamoto Y, Hatanaka Y, Koike H, Nishio K, Yoshikawa K, Uemura H.

Carcinogenesis. 2014 Sep;35(9):2142-53. doi: 10.1093/carcin/bgu143. Epub 2014 Jul 1.


Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production.

Togashi Y, Arao T, Kato H, Matsumoto K, Terashima M, Hayashi H, de Velasco MA, Fujita Y, Kimura H, Yasuda T, Shiozaki H, Nishio K.

Oncotarget. 2014 May 30;5(10):2962-73.


Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer.

Togashi Y, Sakamoto H, Hayashi H, Terashima M, de Velasco MA, Fujita Y, Kodera Y, Sakai K, Tomida S, Kitano M, Ito A, Kudo M, Nishio K.

Mol Cancer. 2014 May 27;13:126. doi: 10.1186/1476-4598-13-126.


Melanoma transition is frequently accompanied by a loss of cytoglobin expression in melanocytes: a novel expression site of cytoglobin.

Fujita Y, Koinuma S, De Velasco MA, Bolz J, Togashi Y, Terashima M, Hayashi H, Matsuo T, Nishio K.

PLoS One. 2014 Apr 10;9(4):e94772. doi: 10.1371/journal.pone.0094772. eCollection 2014.


Osteopontin knockdown in the kidneys of hyperoxaluric rats leads to reduction in renal calcium oxalate crystal deposition.

Tsuji H, Shimizu N, Nozawa M, Umekawa T, Yoshimura K, De Velasco MA, Uemura H, Khan SR.

Urolithiasis. 2014 Jun;42(3):195-202. doi: 10.1007/s00240-014-0649-0. Epub 2014 Mar 12.


The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer.

Hayashi H, Arao T, Togashi Y, Kato H, Fujita Y, De Velasco MA, Kimura H, Matsumoto K, Tanaka K, Okamoto I, Ito A, Yamada Y, Nakagawa K, Nishio K.

Oncogene. 2015 Jan 8;34(2):199-208. doi: 10.1038/onc.2013.547. Epub 2013 Dec 23.


Slug increases sensitivity to tubulin-binding agents via the downregulation of βIII and βIVa-tubulin in lung cancer cells.

Tamura D, Arao T, Nagai T, Kaneda H, Aomatsu K, Fujita Y, Matsumoto K, De Velasco MA, Kato H, Hayashi H, Yoshida S, Kimura H, Maniwa Y, Nishio W, Sakai Y, Ohbayashi C, Kotani Y, Nishimura Y, Nishio K.

Cancer Med. 2013 Apr;2(2):144-54. doi: 10.1002/cam4.68. Epub 2013 Mar 1.


Effects of the Rho kinase inhibitor, hydroxyfasudil, on bladder dysfunction and inflammation in rats with HCl-induced cystitis.

Shimizu N, De Velasco MA, Umekawa T, Uemura H, Yoshikawa K.

Int J Urol. 2013 Nov;20(11):1136-43. doi: 10.1111/iju.12119. Epub 2013 Feb 19.


Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway.

De Velasco MA, Uemura H.

Adv Urol. 2012;2012:419348. doi: 10.1155/2012/419348. Epub 2012 Feb 21.


Modeling porous scaffold microstructure by a reaction-diffusion system and its degradation by hydrolysis.

Garzón-Alvarado DA, Velasco MA, Narváez-Tovar CA.

Comput Biol Med. 2012 Feb;42(2):147-55. doi: 10.1016/j.compbiomed.2011.11.002. Epub 2011 Nov 30.


Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors.

Fujita Y, Islam R, Sakai K, Kaneda H, Kudo K, Tamura D, Aomatsu K, Nagai T, Kimura H, Matsumoto K, de Velasco MA, Arao T, Okawara T, Nishio K.

Invest New Drugs. 2012 Oct;30(5):1878-86. doi: 10.1007/s10637-011-9749-7. Epub 2011 Sep 13.


Supplemental Content

Loading ...
Support Center